Tactile Systems Technology Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名4/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价24.00。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Tactile Systems Technology Inc评分
相关信息
行业排名
4 / 208
全市场排名
45 / 4582
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
买入
评级
20.500
目标均价
+55.07%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Tactile Systems Technology Inc亮点
亮点风险
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
公司代码TCMD
公司Tactile Systems Technology Inc
CEODodd (Sheri L)
网址https://www.tactilemedical.com/
常见问题
Tactile Systems Technology Inc(TCMD)的当前股价是多少?
Tactile Systems Technology Inc(TCMD)的当前股价是 28.920。
Tactile Systems Technology Inc的股票代码是什么?
Tactile Systems Technology Inc的股票代码是TCMD。
Tactile Systems Technology Inc股票的52周最高点是多少?
Tactile Systems Technology Inc股票的52周最高点是30.240。
Tactile Systems Technology Inc股票的52周最低点是多少?
Tactile Systems Technology Inc股票的52周最低点是8.610。
Tactile Systems Technology Inc的市值是多少?
Tactile Systems Technology Inc的市值是645.95M。
Tactile Systems Technology Inc的净利润是多少?
Tactile Systems Technology Inc的净利润为16.96M。
现在Tactile Systems Technology Inc(TCMD)的股票是买入、持有还是卖出?
根据分析师评级,Tactile Systems Technology Inc(TCMD)的总体评级为买入,目标价格为20.500。
Tactile Systems Technology Inc(TCMD)股票的每股收益(EPS TTM)是多少
Tactile Systems Technology Inc(TCMD)股票的每股收益(EPS TTM)是0.773。